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Abstract
Background: Current therapies for cutaneous leishmaniasis are limited by poor efficacy, long-term course of treatment, and
the development of resistance. We evaluated if pentavalent antimony (an anti-parasitic drug) combined with imiquimod (an
immunomodulator) was more effective than pentavalent antimony alone in patients who had not previously been treated.
Methods: A randomized double-blind clinical trial involving 80 cutaneous leishmaniasis patients was conducted in Peru. The
study subjects were recruited in Lima and Cusco (20 experimental and 20 control subjects at each site). Experimental arm:
Standard dose of pentavalent antimony plus 5% imiquimod cream applied to each lesion three times per week for 20 days.
Control arm: Standard dose of pentavalent antimony plus placebo (vehicle cream) applied as above. The primary outcome
was cure defined as complete re-epithelization with no inflammation assessed during the 12 months post-treatment period.
Results: Of the 80 subjects enrolled, 75 completed the study. The overall cure rate at the 12-month follow-up for the
intention-to-treat analysis was 75% (30/40) in the experimental arm and 58% (23/40) in the control arm (p=0.098).
Subgroup analyses suggested that combination treatment benefits were most often observed at the Cusco site, where L.
braziliensis is the prevalent species. Over the study period, only one adverse event (rash) was recorded, in the experimental
arm.
Conclusion: The combination treatment of imiquimod plus pentavalent antimony performed better than placebo plus
pentavalent antimony, but the difference was not statistically significant.
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Introduction
Leishmaniasis includes a spectrum of diseases occurring
throughout Asia, Africa, and the Americas which are caused by
infection with Leishmania parasites transmitted by the bite of
infected sandflies [1]. Disease manifestations are determined
predominantly by the host’s immune response and the parasite
species [2]. In Peru, the predominant species include the Leishmania
(Viannia) complexes of L. braziliensis, L. peruviana and L. guyanensis
that are all associated with cutaneous leishmaniasis. Mucocutane-
ous leishmaniasis is caused predominantly by L. braziliensis
infection [3,4].
There is no vaccine for leishmaniasis and current therapies are
limited by poor efficacy, the requirement for prolonged treatment,
and increasing development of clinical resistance. The drugs most
commonly used include pentavalent antimonials, various ampho-
tericin B lipid formulations and a variety of other drugs used to a
lesser extent, including pentamidine, miltefosine, and paromomy-
cin [5]. In Peru, the most commonly used first-line treatment for
cutaneous and mucocutaneous leishmaniasis is pentavalent
antimony (meglumine antimoniate or sodium stibogluconate) with
a success rate varying between 60% and 80% [6]. Amphotercin B
is typically used in those patients who do not respond to
pentavalent antimony. The current standard treatment regimes
for cutaneous leishmaniasis all involve monotherapy. The use of
combination therapy may improve efficacy, and if toxic drugs can
be used at lower levels, improve tolerance.
Host immune mechanisms play an important role in the efficacy
of anti-Leishmania chemotherapy [reviewed in 7]. An essential
component of cell-mediated immunity against Leishmania is the
development of a Th1 type response that activates macrophages
via IFN-c to either inhibit or kill the parasite [2]. Activation of the
innate immune response is essential for the subsequent develop-
ment of the Th1 type cell-mediated immune response. Imiquimod
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7/8) on antigen-presenting cells and mediates the production of a
variety of cytokines including IFN-a, IFN-c, TNF-a, IL-1 and IL-
12 leading to the induction of enhanced Th1 immune responses
[8,9]. In addition, it has been demonstrated that imiquimod can
directly activate macrophage killing of Leishmania amastigotes in
the absence of a T-cell-mediated response [10]. Enhancing the
local immune response at the site of cutaneous infection, therefore,
may be a logical approach to enhance parasite clearance.
We previously reported that combination therapy with
imiquimod plus parental pentavalent antimony was more effective
than pentavalent antimony alone in patients who had previously
failed treatment with pentavalent antimony [11]. The objective of
this clinical trial was to determine whether the combination
therapy can also be beneficial for cutaneous leishmaniasis patients
who have not previously been treated.
Methods
Trial Design
The study design was a randomized controlled trial where 80
subjects were recruited at two clinics associated with the leishman-
iasis clinic at the Instituto de Medicina Tropical ‘Alexander von
Humbolt’ - Universidad Peruana Cayetano Heredia (UPCH) –
Hospital Nacional Cayetano Heredia (in Lima and in Cusco, Peru).
Subjects recruited in Lima are typically infected with L. peruviana, L.
guyanensis,o rL. braziliensis while those recruited at the Cusco site are
infectedpredominantlywithL.braziliensis[12].Wethereforeplanned
to analyze the data overall and for the Lima and Cusco sites
individually. Each clinic recruited 20 experimental and 20 control
subjects and assigned treatment based on a 1:1 randomization list
generated by 3M Pharmaceuticals Inc. Subjects assigned to the
control arm received the standard pentavalent antimony treatment
plus an application of placebo vehicle cream applied to each lesion 3
times per week. Subjects assigned to the experimental arm received
pentavalent antimony plus5% imiquimod cream identically applied.
Study I.D. numbers and corresponding treatment packages were
prepared so that both subjects and study investigators were blind to
treatment allocation throughout the study. Although diagnostic and
clinical procedures were performed in either Lima or Cusco, most
subjects were recruited from smaller communities of within a one
day’s drive (e.g. Ancash, Churin, Yumpe, Cajatambo, Yauyos,
Sicuani,Madre de Dios and surrounding areas). Study teamsat each
cliniccomprised doctors, nurses, and technologists, all of whomwere
supervised by Dr. Llanos-Cuentas. Following the completion of
therapy, follow-up visits were scheduled at 1, 2, 3, 6, 9 and 12
months. The primary outcome was cure, defined as complete re-
epithelization with no inflammation.
Eligibility Criteria
The following inclusion and exclusion criteria were assessed
using a pre-screening protocol to determine patients’ eligibility.
Inclusion criteria:
a) Males and females between 5 and 65 years of age
b) Confirmed diagnosis of cutaneous leishmaniasis (i.e. presence
of an active ulcerative cutaneous Leishmania lesion, and a
positive identification of the parasite from the lesion. (smear
microscopy, culture, or PCR)
c) Duration of disease more than 4 weeks.
d) No prior therapy with anti-Leishmania drugs.
e) Female patients of childbearing age: a negative urine
pregnancy test, not breastfeeding, required to use adequate
contraception during the 20-day treatment.
f) Informed written consent (self or parent for under-18 year-
olds) for the trial and a separate additional consent for photos
of lesions (at baseline and at follow-up time points).
g) Willing to participate in all treatment and follow-up visits,
and be reachable by study personnel.
Exclusion criteria:
a) Lesion(s).2,500 mm
2.
b) More than 6 cutaneous lesions.
c) Mucosal lesion.
d) Previous exposure to imiquimod or anti-Leishmania treatment.
e) Participation in another experimental protocol and/or had
received investigational products within previous 30 days.
f) History of any acute or chronic illness (other than cutaneous
leishmaniasis) or medication that, in the opinion of the
investigators, may interfere with the evaluation of the trial
(e.g. history of heart or liver illness).
g) History of significant psychiatric illness.
h) History of previous anaphylaxis or severe allergic reaction to
one or more of the proposed drugs.
i) Unlikely to cooperate with the requirements of the study
protocol.
j) Concomitant infection (i.e. bartonellosis, sporotrichosis,
mycobacterial infection)
Before enrollment, subjects also underwent an electrocardio-
gram and blood sampling for limited biochemical analysis (eg.
ALT, AST, total bilirubin, alkaline phosphatase, pancreatic
amylase, glucose and creatinine). When a bacterial superinfection
was suspected at the site of Leishmania infection, subjects received
oral or systemic antibiotic treatment (dicloxacillin or clindamycin)
before entry into the trial (during the screening period).
Baseline Measurements
Subjects who met all inclusion/exclusion criteria underwent a
limited physical exam to ensure that no mucosal lesion had
developed. Borders around each lesion were drawn using a plastic
sheet placed on the lesion to accurately document size. Lesions
were photographed with a digital camera (at daylight setting (no
flash) at a distance of 15 cm, with patient ID code and date clearly
Author Summary
Neglected tropical diseases (NTDs) are a group of tropical
infections including trypanosomiasis, filariasis, schistoso-
miasis, onchocerciasis, leishmaniasis and other such
diseases of poverty. Of the classic neglected diseases,
leishmaniasis has among the highest level of morbidity
and mortality. Infection with Leishmania parasites causes
severe disease in humans, including fatal visceral leish-
maniasis and cutaneous leishmaniasis resulting in severe
scarring, often in the face. This is a difficult infection to
treat because the current therapies are generally poorly
effective. The present study carried out a placebo-
controlled, double-blinded study to investigated whether
a combined therapy with imiquimod plus pentavalent
antimony was superior to the standard therapy of
pentavalent antimony alone as a first-line treatment for
cutaneous leishmaniasis in Peru. A higher cure rate with
the combination therapy was observed, but could not be
conclusively proven.
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computer at UPCH in Lima. A punch biopsy specimen was taken
from the border of the lesion prior to the first treatment and a
section placed into media to culture the parasite.
Treatment
Antimonial treatment. All subjects received pentavalent
antimony. The dose of 20 mg sodium stibogluconate (Albert
David, Kolkata, India) per kg body weight/day was administrated
intravenously for 20 consecutive days. Because a total of 20
injections were administered, care was taken to ensure that
injections were not administered in the same exact location.
Imiquimod and placebo cream treatments. The
treatment sachets containing the assigned topical cream for each
patient were opened at the time of each treatment and the imiquimod
or placebo vehicle cream (3M Pharmaceuticals Inc.) applied to the
cutaneous lesion. Both creams were identical in appearance. At each
treatment, the study nurse cleaned the lesion using sterile saline
solution to remove debris or scab and then applied the cream on the
entire area of each lesion including a 0.5 cm margin of normal skin,
using a gloved finger. The cream was applied in the morning and
rubbed into the lesion(s) until no longer visible. Each sachet contained
250 mg of cream (with or without active imiquimod) and each lesion
received between 125–250 mg of cream. Topical treatment was
applied three times per week (i.e. Monday, Wednesday, Friday or
Tuesday, Thursday and Saturday) for a total of 9 applications during
the 20-day course of treatment with pentavalent antimony. Only new
unopened sachets were used for each treatment.
The lesion(s) remained uncovered for at least 30 minutes
following each application during which time the study doctor
Figure 1. Trial flowchart.
doi:10.1371/journal.pntd.0000491.g001
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the face were covered with an occlusive dressing (Tegaderm, 3M
Pharmaceuticals Inc.) to prevent cream removal by clothing. The
patients were instructed to remove the dressing and wash the
lesions with warm soapy water approximately 8 h following
treatment, as well as each morning. After each treatment, the
study doctor evaluated the patient for 30 minutes and the patient
was encouraged to continue his/her daily activities.
Evaluation of Clinical Response
The primary outcome was cure defined as complete re-
epithelialization with no inflammation assessed at between 1 and
12 months post-treatment. The clinical response was evaluated
using standard criteria for assessing the size and severity of the
cutaneous lesion including size of lesion, reduced ulceration, re-
epithelialization, and inflammation reduction. The criteria used to
evaluate the response to treatment have been used for the past
several years by the investigators [7,8] as follows.
M0: No improvement. The lesion is asctive and has the same
characteristics of has become larger than before the start of
treatment.
MI: The size of the lesion is decreased ,50% in comparison
with the initial lesion. Less inflammatory signs with discrete re-
epithelialization.
M2: The size of the lesion is decreased between 50–90% in
comparison with the initial lesion. Few inflammatory signs, less
than M1.
M3: The size of the lesion is decreased more than 90% with re-
epithelialization and very little inflammation.
M4: Complete re-epithelialization with a characteristic scar and
no inflammation.
Ateachofthefollow-up time points(ie. at1, 2,3,6, 9, 12 months),
the overall response to therapy was classified as: Improvement, Cure
or Failure based on the characteristics listed below:
Improvement: Significant reduction in the size of the lesion at
the time of evaluation (Stages M1–M3) compared to baseline.
Cure: Complete re-epithelialization of the lesion without
inflammation (Stage M4).
Failure: Any one, or combination, of the following options:
i) Stage MO at 1 month of follow-up after the treatment
ii) Stage M1 at 3 months of follow-up after the treatment
iii) Regression of the clinical stage to a lower stage or
development of a new lesion.
Safety and Tolerability Evaluation
Local side effects of the topical treatment at the application site
(pain, pruritus, erythema and swelling) were graded as follows:
Grade 0=none; Grade 1=mild (easily tolerated); Grade 2=mod-
erate (sufficiently discomforting to interfere with daily activities);
Grade 3=severe (prevents normal daily activity).
Follow-Up Evaluations
At each follow-up visit after the preceding treatment, a lesion
evolution score was assigned based on the least improved lesion in
Table 1. Baseline demographic characteristics of subjects with leishmaniasis treated with imiquimod 5% cream plus pentavalent
antimony versus placebo cream plus pentavalent antimony, participating in a randomized trial, Peru, 2006–7.
Characteristic Imiquimod plus pentavalent antimony Placebo plus pentavalent antimony
(n=40) (n=40)
Age (in years)
Mean6SD 25.0610.3 25.9610.4
Range (6 to 52) (4 to 52)
Sex (no. of subjects)
Male 31 31
Female 9 9
Study site (no. of subjects)
Lima 20 20
Cusco 20 20
Occupation (no. of subjects)
Agriculture 22 26
Professional 2 1
Mining 4 4
Student 2 1
Tourism 6 7
Other 4 1
Region where leishmaniasis was acquired (no. of subjects)
a
Mountains 5 9
Jungle 35 31
No. subjects who completed 20-day combination therapy with
pentavalent antimony plus the imiquimod or placebo cream
39 39
aMountains include the Andes between 1000 and 2500 meters above sea level; Jungle includes the Amazonian forest between 0 and 1000 meters above sea level.
doi:10.1371/journal.pntd.0000491.t001
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the clinical report form (CRF). This evaluation included
measuring the size of the lesion(s) and taking a standardized
photograph of each lesion. A limited physical examination was
also performed, recording all adverse events experienced since the
last follow-up visit.
Parasite Diagnosis and Species Identification
The clinical diagnosis of cutaneous leishmaniasis was confirmed
in all patients by directly identifying the parasite by smear (Giemsa
staining), by culture (in Novy-Macneal Nicolle media), and/or by
PCR of the Leishmania minicircle DNA prior to randomization.
Leishmania species determination was possible in those cases where
the parasite was successfully cultured from the lesion. To
differentiate between infections with L. braziliensis, L. peruviana,
and L. guyanensis, the mannose phosphatase isomerase isoenzyme
(MPI) gene was sequenced from the cultured parasites. The MPI
enzyme represents the only isoenzyme identified by Multi Locus
Enzyme Electrophoresis (MLEE) to differentiate these species [12]
and it has recently been established that the sequence of the MPI
gene could differentiate between infections with these different
species [13,14]. All parasite species determinations were per-
formed before the treatment blind was broken.
Statistical Analysis
Sample size was estimated such that the log-rank test for
equality of survival curves would have 80% power to detect a
statistically significant difference in proportions cured at three
months of at least 32% (hazard ratio of 2.6) (estimates of
proportions cured at 3 months were based on previously published
data) [11]. This test assumes a constant hazard ratio over time.
Descriptive statistics (means6standard deviations (SD) and
proportions) were calculated to summarize socio-demographic,
clinical and epidemiological characteristics of patients at baseline
for experimental and control arms. These characteristics included
age, sex, study site, region of infection acquisition, occupation and
lesion-specific data (number, location, size, type, duration,
presence of adenopathy and presence of bacterial superinfection).
Intention-to-treat and efficacy analyses were conducted. The
intention-to-treat analysis was the primary analysis. In this
analysis, missing values at day 20 were treated as failures and
any subsequent missing value was assigned the outcome status of
the patient’s most recent visit. The effect of this decision in dealing
with missing values, was examined in a secondary intent-to-treat
analysis where all non-cured categories (missing and not
improved/worse) were considered failures. Additional secondary
analyses were performed. This included an efficacy (per protocol)
Table 2. Baseline characteristics of lesions in subjects with leishmaniasis treated with imiquimod 5% cream plus pentavalent
antimony versus placebo plus pentavalent antimony, participating in a randomized trial, Peru, 2006–7.
Characteristic Imiquimod plus pentavalent antimony Placebo plus pentavalent antimony
(n=40) (n=40)
Number of lesions 79 80
Mean6SD 1.9861.37 2.0061.47
Median (range) 1 (1 to 6) 1 (1 to 6)
Location of lesion, no. of lesions
Face 12 13
Upper extremity 23 19
Lower extremity 41 33
Torso
* 01 4
Pelvis 3 1
Duration of the disease, months
Mean6SD 2.8462.20 3.5063.32
Median (range) 2 (.1 to 10.0) 2 (.1 to 15.0)
Area of lesions (total area per lesion), mm
2
Mean6SD 146.246270.50 178.346278.75
Median (range) 66 (0 to 1913) 61 (0 to 1554)
Type of lesion, no. of lesions
Ulcer 78 74
Nodule 1 4
Verrucose 0 1
Scar 0 1
Adenopathy, no. of lesions
Present 29 25
Absent 50 55
Bacterial superinfection, no. of lesions#
Present 9 1
Absent 70 79
doi:10.1371/journal.pntd.0000491.t002
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each timepoint using chi-square tests. The log rank test was used to
compare the Kaplan-Meier survival curves.
Ethics Review Board Approval and Informed Consent
The experimental protocol for this study was designed in
accordance with the general ethical principles outlined in the
Declaration of Helsinki, 2000 and ICH (International Committee
for Harmonization) guidelines for Good Clinical Practice.
Approvals from the ethics review boards of Universidad Peruana
Cayetano Heredia UPCH, McGill University, and the National
Institute of Health in Peru (INS-Peru) were obtained prior to the
initiation of the study. The UPCH and INS review committees
approved a Spanish version of the consent form. The study
investigators explained the nature of the investigation and the risks
involved to each patient, or parent of a patient below 18 years of
age, prior to recruitment. Written informed consent was obtained
from each patient enrolled in the study and the patient/parent was
informed that he/she was free to voluntarily withdraw from the
study at any time.
Study Monitoring
Program directors from DNDi and a study monitor employed
by DNDi periodically reviewed study documentation (ie. all CRFs
and SOPs and corresponding source documents for each patient)
and implementation procedures. The monitoring visits provided
DNDi with the opportunity to evaluate the progress of the study,
verify the accuracy and completeness of CRFs, resolve any
inconsistencies in the study records, as well as to ensure that all
protocol requirements, applicable regulations, and investigators’
obligations were fulfilled.
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ticals Inc. provided the randomized allocation of imiquimod and
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the manuscript.
Results
Patient recruitment took place between December 2005 and
June 2006; follow-up continued to June 2007. From the 157
patients screened, 80 patients met the inclusion/exclusion criteria,
78 (97.5%) completed the 20-day course of treatment, and 75
(93.8%) were followed for the entire 12 months following the end
of therapy (Figure 1). The demographic characteristics of the
patients are presented in Table 1. There were no significant
differences between the intervention groups.
The principal characteristics of the lesions are presented in
Table 2. On average, each patient had 2 lesions. The mean
duration and sizes of the lesions were not judged to be different
between the experimental: antimony/imiquimod and control:
antimony/placebo groups. There were more lesions on the torso
in the control: antimony/placebo group (n=14 lesions in 5
subjects) than in the experimental: antimony/imiquimod group
(n=0). There were more lesions with bacterial super-infections in
the experimental: antimony/imiquimod group (n=9 lesions in 4
subjects) than in the control: antimony/placebo group (n=1).
There is no evidence to suggest that these differences could have
influenced the outcome of the trial.
There were no significant differences between the intervention
groups with respect to adverse events at the site of application
(Table 3). One patient in the experimental antimony/imiquimod
group however had a serious adverse event and was unable to
complete the full course of treatment. This was a 39-year-old male
who developed a generalized rash on day 9 of treatment, at which
time treatment was suspended and he was treated with anti-
histamines. After the rash subsided, treatment resumed on day 13
but was discontinued the next day when the rash returned and
again treated with anti-histamines to resolve the rash. He was then
given only imiquimod cream for the remainder of the 20 days
Table 3. Adverse effects experienced by subjects with leishmaniasis treated with imiquimod 5% cream plus pentavalent antimony
versus placebo cream plus pentavalent antimony, participating in a randomized trial, Peru, 2006–7.
Adverse effect Imiquimod plus pentavalent antimony Placebo plus pentavalent antimony P-value
(n=40) (n=40)
Adverse effect 0.654
Any 20 18
None 20 22
Swelling 0.617
Yes 12 10
No 28 30
Itching 0.793
Yes 10 9
No 30 31
Pain 0.745
Yes 5 6
No 35 34
Erythema 0.626
Yes 13 11
No 27 29
doi:10.1371/journal.pntd.0000491.t003
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to the pentavalent antimony. At the 2-month follow-up period, this
patient was considered a treatment failure and was given
amphotericin B, which resulted in a complete cure with no rash.
He was considered to be a treatment failure in the final analysis.
The evolution of the lesions by intervention group is detailed in
Table 4. Most missing values occurred at month 2 (n=28), but at
the 12-month evaluation, outcome data were obtained from 75 of
the 80 patients. In the primary intention-to-treat analysis (Table 5),
the overall cure rate was 75% (30/40) in the experimental:
antimony/imiquimod group compared to 58% (23/40) in the
control: antimony/placebo group (p=0.098) at 12 months. In the
secondary intention-to-treat analysis (Table 4), where all non-
cured categories (missing, not improved/worse) were considered
failures, a statistically significant difference was found in cure rates
between the two groups at 12 months.
We further performed an efficacy analysis where the patients
who did not complete the treatment (one from each group) and
Table 4. Response of lesions to treatment among subjects treated with imiquimod 5% cream plus pentavalent antimony versus
placebo cream plus pentavalent antimony, intention-to-treat analysis (missing=failures).
Time after the end of therapy, response No. (%) of subjects P-value1
Imiquimod plus pentavalent antimony Placebo plus pentavalent antimony
(N=40) (N=40)
At day 20
Missing* 1 1
Not improved/worse
a 00
Improved
b 37 32
Cured
c 27
At month 1
Missing* 6 5
Not improved/worse 1 4
Improved 16 18
Cured 17 (43%) 13 (33%) .488
At month 2
Missing* 10 18
Not improved/worse 3 5
Improved 3 5
Cured 24 (60%) 12 (30%)
At month 3
Missing* 1 3
Not improved/worse 8 13
Cured 31 (78%) 24 (60%) 0.148
At month 6
Missing* 1 2
Not improved/worse 9 13
Cured 30 (75%) 25 (63%)
At 9 months
Missing* 1 4
Not improved/worse 9 13
Cured 30 (75%) 23 (58%)
At month 12
Missing* 1 4
Not improved/worse
c 91 5
Cured 30 (75%) 21 (53%) 0.036
*Missing includes, at day 20, subjects who did not complete treatment; for all other timepoints, missing also includes those not observed and those lost-to-follow-up.
aNot improved/worse is considered a treatment failure and was defined at 1 month post-treatment as an active lesion, unchanged or worse, compared with its
characteristics at the start of treatment; at 3 months post- treatment, as a lesion that has been reduced in size by not more than approximately 50%, although having
less inflammatory signs with discrete re-epithelialization compared to the start of treatment; at 6 months and later time points, as a lesion that had regressed to a lower
clinical stage or the development of a new lesion.
bImproved is defined as significant reduction in the size of the lesion at the time of evaluation compared to baseline.
cCured is defined as complete re-epithelialization of the lesion without inflammation.
1p-values are based on the chi-square analysis comparing cure rates between the two intervention groups, where all those missing and those not improved/worse are
considered as failures.
doi:10.1371/journal.pntd.0000491.t004
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group) were not considered in the analysis. In this analysis, the
cure rate at the final 12-month follow-up was 77% (30/39) in the
experimental antimony/imiquimod group and 58% (21/36) in the
control antimony/placebo group (p=0.085).
Figure 2 displays the Kaplan-Meier (KM) curves depicting time
to cure for each group within the 12-month period following
enrolment into the study. Relapses (n=3) were considered failures
throughout. Missings were considered as described for Table 5.
The log rank test comparing the KM curves of the two groups
revealed a non- statistically significant result (p=0.174), although
the combined therapy group demonstrated a higher probability of
cure compared to the placebo group.
Patients who did not respond to therapy after 2–3 months
follow-up were treated with amphotericin B, and all infected
lesions were cured. All of these subjects were considered as
treatment failures in the intention-to-treat analyses.
Analysis by treatment center (intention-to-treat, primary analysis)
revealed that, at 12 months, the Lima cohort had a 75%cure ratein
the experimental: antimony/imiquimod group compared to 65% in
the control: antimony/placebo group (p=0.490) (Table 6). In
comparison, the Cusco cohort had a 75% cumulative cure rate in
the experimental: antimony/imiquimod group compared to a 50%
cure rate in the control: antimony/placebo group (p=0.102).
Efficacy analysis for the Cusco cohort, removing patients who did
not complete therapy or were lost to follow-up, showed a cure rate
in the experimental: antimony/imiquimod group of 79% (15/19)
compared to 47% (8/17) in the control: antimony/placebo group
(p=0.046).
The major difference between treatment center appeared to be
the lower cure rate in the Cusco control: antimony/placebo group.
Baseline characteristics of the lesions from the patients from Lima
and Cusco are shown in Table 7 and show that the lesions were,
on average, larger in the Cusco cohort. L. braziliensis infections are
generally more difficult to cure and have a higher relapse rate than
L. peruviana and L. guyanensis infections and could account for the
lower cure rate in the Cusco control: antimony/placebo group (6,
15). Species determination, performed as previously detailed
[14,15] on 28 cultures established from patient lesions revealed
that L. braziliensis infections were present in 11 of 12 subjects from
Cusco and 5 of 16 from Lima (Figure 3). The distribution of
infecting species was consistent with prior studies showing that
patients in Cusco are predominantly infected with L. braziliensis
[12,16] and this could also explain why the lesions from the Cusco
cohort were on average larger than the lesions from the Lima
cohort.
Discussion
This study assessed whether the combination of topical
imiquimod plus systemic pentavalent antimony was superior to
monotherapy with pentavalent antimony as a first-line treatment
for cutaneous leishmaniasis in Peru. The final outcome did not
reach statistical significance in the intention-to-treat analysis,
although the combination therapy did have a higher cure rate. In
the planned subset analysis by site, there was a similar suggestion
that the combination therapy was superior to monotherapy in the
Cusco cohort which was predominantly infected with L. braziliensis,
a species usually more difficult to treat than L. peruviana and L.
guyanensis [6]. The results from this trial are consistent with a
previous open-label pilot trial involving this combination therapy
as a first-line therapy for cutaneous leishmaniasis in Peru [17] as
Figure 2. Survival curves comparing imiquimod 5% cream plus
pentavalent antimony (dashed line) versus placebo cream plus
pentavalent antimony (solid line) in a randomized trial, Peru,
2006–2007. Note: Relapses (n=3) were considered failures through-
out since once they are cured they could not be brought back into the
Kaplan-Meier analysis. Missing at day 20 were considered failures (n=2);
for all other timepoints, missing were considered to have the outcome
status of their most recent visit.
doi:10.1371/journal.pntd.0000491.g002
Table 5. Response of lesions to treatment among subjects treated with imiquimod 5% cream plus pentavalent antimony versus
placebo cream plus pentavalent antimony, intention-to-treat analysis (missing=last value carried forward).
Number cured at each timepoint (%) No. (%) of subjects P-value1
Imiquimod plus pentavalent antimony Placebo plus pentavalent antimony
(N=40) (N=40)
Day 20 2 (5%) 7 (18%) 0.077
Month 1 17 (43%) 14 (35%) 0.491
Month 2 28 (70%) 21 (53%) 0.108
Month 3 31 (78%) 24 (60%) 0.091
Month 6 30 (75%) 24 (60%) 0.152
Month 9 30 (75%) 25 (63%) 0.227
Month 12 30 (75%) 23 (58%) 0.098
*Missing at day 20 are considered failures; for all other timepoints, missing are considered to have the outcome status of their most recent visit.
1p-values are based on the Pearson chi-square analysis comparing cure rates between the two intervention groups.
doi:10.1371/journal.pntd.0000491.t005
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[11,18].
An important consideration of this study is that activation of a
toll like receptor (TLR) is therapeutically beneficial in the
treatment of this parasitic infection and this could have
implications beyond leishmaniasis. Activation of TLR 7/8 with
imiquimod could work in at least two ways to enhance resolution
of Leishmania infections. First, it could directly stimulate macro-
phages to synthesize nitric oxide resulting in direct killing of the
parasite, as previously detailed in Leishmania-infected cultured
macrophages [10]. Secondly, imiquimod could mediate a better
anti-Leishmania Th1 immune response that would result in the
production of IFN-c and macrophage activation resulting in
enhanced parasite killing. This would be consistent with the
observation that topical imiquimod, used as a vaccine adjuvant
with a killed Leishmania preparation, has been shown to enhance
the Th1 immune response against a subsequent live infection with
L. major in BALB/c mice [19]. Since the immune status of
leishmaniasis patients is known to affect drug efficacy [7], the
parasite killing by pentavalent antimony plus the enhanced innate
and/or acquired immune response against Leishmania could be
expected to act synergistically to increase the cure rate and/or
reduce the relapse rate.
We have previously observed that treatment with imiquimod
alone had a transient beneficial effect as determined by a reduction
in lesion size in the first few days of treatment but did not
ultimately clear the infection [17]. This has also been observed for
Old World cutaneous leishmaniasis [20]. This could suggest that
imiquimod can activate an initial innate immune response as
previously observed in infected and non-infected macrophages in
vitro [10,21]. Future studies should include analyses of relevant
immunological parameters in the infected lesions treated with
topical imiquimod to provide a better understanding of how
imiquimod enhances cure and possibly define more effective
therapy regimes.
An interesting observation was that there was a higher failure
rate in the control: antimony/placebo group in the Cusco cohort
compared to the Lima cohort. This could be related to the
predominance of L. braziliensis in Cusco as observed in this and
previous studies [12,16]. As there is a higher failure and/or relapse
rate with L. braziliensis infections than with L. peruviana or L.
guyanensis infections [6,15], it is possible that the combination
therapy may have reduced the relapse rate associated with L.
braziliensis infections in the Cusco cohort. However, in addition to
the different species, there may be other differences between the
two sites that necessitate a larger sample size. In any event, if the
Table 6. Cure rate at the 12-month follow-up time point: By site.
pentavalent antimony plus imiquimod pentavalent antimony plus placebo
Patient status at 12 months: Intention-to-treat analysis
OVERALL
Number of patients 40 40 80
Cured 30 23
Failed 10 17
LIMA
Number of patients 20 20 40
Cured 15 (75%) 13 (65%)
Failed 5 7 X
2=0.476; p=0.490
CUSCO
Number of patients 20 20 40
Cured 15 (75%) 10 (50%)
Failed 5 10 X
2=2.667; p=0.102
*Missing at day 20 are considered failures; for all other timepoints, missing are considered to have the outcome status of their most recent visit.
1p-values are based on the chi-square analysis comparing cure rates between the two intervention groups.
doi:10.1371/journal.pntd.0000491.t006
Figure 3. Distribution of the 28 speciated Leishmania infections,
by site.
doi:10.1371/journal.pntd.0000491.g003
Table 7. Baseline characteristics of subjects with
leishmaniasis, by study site (Lima and Cusco).
LIMA CUSCO
Age (mean in years) 24.6 26.3
Sex (% male) 68 88
Duration (mean in months) 3.45 3.10
Number of lesions per patient (mean) 2.03 1.93
Size of lesions (mean in mm
2) 119.4 213.6
doi:10.1371/journal.pntd.0000491.t007
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infections, it would be necessary to implement a pre-treatment
species determination.
Two previous studies using the combination of imiquimod with
pentavalent antimony have been carried out in Iran in areas
endemic for L. tropica. One study reported that there was no
beneficial effect [22] and the other study reported a beneficial
effect of the combination therapy [23]. It is difficult to compare
our Peruvian study with these results as there were differences in:
definitions for cure, methods of administration of the pentavalent
antimony, length of follow-up, and prevalent Leishmania species. It
is noteworthy that, in Iran, L. tropica is resistant to pentavalent
antimony treatment [24] and this could further complicate the
interpretation of the outcome. It would, however, be of interest to
carry out an imiquimod combination immunotherapy trial in the
Old World involving L. major infections that are responsive to
pentavalent antimony or in combination with other anti-Leishmania
treatments.
There was one adverse event that resulted in deviation from the
treatment protocol when a generalized skin rash developed in one
patient in the experimental (antimony/imiquimod) group. The
rash resolved when the pentavalent antimony treatment was
stopped and the patient continued to be treated with topical
imiquimod alone. This patient was eventually considered a
treatment failure at 2 months follow-up and was counted as a
failure in the experimental group even though he had not received
the complete course of combination therapy.
Future studies should include combining topical imiquimod
with other therapies for cutaneous leishmaniasis such as, for
example, with topical paromomycin or oral miltefosine. If the cure
rate with a combined imiquimod/paromomycin or imiquimod/
miltefosine therapy reaches a cure rate of 80% at 3 months post-
treatment, then this can be used to replace pentavalent antimony
as the first-line treatment in Peru. Pentavalent antimony could
then be used only in those cases that do not respond to the
combination topical therapy.
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